Author

M. B. Khan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 3 Biophysics· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:proteomics· 4 Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Approach:mechanistic / dynamical model· 1

Frequent Co-Authors

H. S. Young· 4 shared M. J. Lemieux· 4 shared E. Arutyunova· 3 shared J. C. Vederas· 3 shared T. Lamer· 3 shared C. Fischer· 2 shared D. L. Tyrrell· 2 shared J. Lu· 2 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersBiochemistry

H. S. Young

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

SARS-CoV-2 Mpro protease variants of concern display altered viral and host target processing but retain potency towards antivirals

S. A. Chen, E. Arutyunova, J. Lu, M. B. Khan, W. Rut, M. Zmudzinski, S. Shahbaz, J. Iyyathurai, E. Moussa, Z. Turner, B. Bai, T. Lamer, J. A. Nieman, J. C. Vederas, O. Julien, , M. J. Lemieux

The paper examines how SARS-CoV-2 Mpro variants affect viral and host protein processing but maintain antiviral potency.

bioRxiv · Jan 28, 2023 · PreprintBiochemistry

N-Terminal finger stabilizes the reversible feline drug GC376 in SARS-CoV-2 Mpro

E. Arutyunova, M. B. Khan, C. Fischer, J. Lu, T. Lamer, W. Vuong, M. J. van Belkum, R. T. McKay, D. L. Tyrrell, J. C. Vederas, H. S. Young, M. J. Lemieux

This study characterizes the reversible inhibition of SARS-CoV-2 and SARS-CoV Mpro by GC376, showing nanomolar Ki values and domain swapping in the drug-bound structures.

bioRxiv · Feb 16, 2021Biophysics

Sarcolambans are phospholamban- and sarcolipin-like regulators of the sarcoplasmic reticulum calcium pump SERCA

J. J. Bak, R. Aguayo-Ortiz, M. B. Khan, S. L. Robia, M. J. Lemieux, L. M. Espinoza-Fonseca, H. S. Young

The paper investigates sarcolamban peptides from invertebrates to determine their regulatory effects on SERCA1a, finding they act as super-inhibitors with phospholamban-like or sarcolipin-like characteristics.

bioRxiv · Jul 19, 2020 · PreprintBiochemistry

Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication

W. Vuong, M. B. Khan, C. Fischer, E. Arutyunova, T. Lamer, J. Shields, H. A. Saffran, R. T. McKay, M. J. van Belkum, M. Joyce, H. S. Young, D. L. Tyrrell, J. C. Vederas, M. J. Lemieux

This paper shows that feline coronavirus drugs inhibit SARS-CoV-2 main protease and block virus replication in cell culture with low toxicity.

bioRxiv · May 3, 2020Biochemistry

Plasma-derived HIV Nef+ exosomes persist in ACTG384 study participants despite successful virological suppression.

A. D. Raymond, M. J. Lang, J. Chu, T. Campbell-Sims, M. B. Khan, V. C. Bond, R. B. Pollard, D. M. Asmuth, M. D. Powell

The paper measures Nef+ exosomes in HIV+ patients on ART and finds they persist despite viral suppression and correlate with CD4 recovery patterns.

bioRxiv · Jul 20, 2019 · PreprintMicrobiology